

Cover Story
By Matthew Bin Han Ong
The vast majority of patients with prostate cancer in the United States don't receive androgen deprivation therapy injections on time. Up to 84% of injections are delayed for patients on a 28-day schedule, according to an authoritative study published in the The Journal of Urology.
In Brief
Clinical Roundup
Drugs & Targets


Trending Stories
- She flew Black Hawks and battled cancer—now Col. Susan Fondy grapples with cuts to lymphedema research
- Rick and Mary Pazdur on facing “the other side of the stethoscope”
A few months before Mary died of ovarian cancer, the couple shared how this experience shaped their perspectives on oncology - Imaging’s ride to the bottom in clinical trials—and why it matters now
- NIH says it’s moving away from animal-based models
- The Directors: Mark Evers and Steven Libutti on riding out the tempest—and maintaining research momentum
As oncology braces for funding, Medicaid cuts, these two directors tell young investigators not to panic - ODAC nixes GSK’s Blenrep myeloma regimens, citing ocular toxicity, dosing, applicability to U.S. population